Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Cash from Financing Activities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Cash from Financing Activities for 4 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 33.85% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Dec 2025, up 161.82% year-over-year, with the annual reading at $14.7 million for FY2025, 161.82% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $1.3 million at bioAffinity Technologies, down from $9.3 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $15.0 million in Q3 2022, with the low at -$563556.0 in Q4 2022.
  • Average Cash from Financing Activities over 4 years is $2.1 million, with a median of $666669.5 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities plummeted 127.65% in 2023, then surged 3412.08% in 2025.
  • Over 4 years, Cash from Financing Activities stood at -$563556.0 in 2022, then surged by 84.95% to -$84805.0 in 2023, then soared by 2488.86% to $2.0 million in 2024, then plummeted by 33.85% to $1.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $1.3 million, $9.3 million, and $3.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.